Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

BACKGROUND: Many studies have explored the cost-effectiveness of immunotherapy versus chemotherapy alone. However, there is paucity of evidence on direct pharmacoeconomic studies related to immunotherapy combinations. Thus, we aimed at assessing the economic outcomes of first-line immunotherapy comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Wen, Song, Ruomeng, Tao, Hongyu, Gao, Zhixiang, Zhu, Min, Zhang, Mingyue, Wu, Huazhang, Gong, Daichen, Zhang, Xiyan, Cai, Yuanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186643/
https://www.ncbi.nlm.nih.gov/pubmed/37189081
http://dx.doi.org/10.1186/s12885-023-10938-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186643/
https://www.ncbi.nlm.nih.gov/pubmed/37189081
http://dx.doi.org/10.1186/s12885-023-10938-8

Ejemplares similares